B Cell Design SAS - ArkAb of Limoges at MEDICA 2017 in Düsseldorf -- COMPAMED Trade Fair
Manufacturers Service

B Cell Design SAS - ArkAb

Bât EFS, 98, rue Charles le Gendre, 87000 Limoges
France

Telephone +33 5 55123021
contact@arkab.fr

This company is co-exhibitor of
Business France

Hall map

MEDICA 2017 hall map (Hall 3): stand H64

Fairground map

MEDICA 2017 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.01  Allergies

Allergies

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.03  Auto-immune diseases

Auto-immune diseases

  • 03  Diagnostics
  • 03.05  Infectious Immunology
  • 03.05.04  Controls / Standards / Calibrators - Infect. immunology

Controls / Standards / Calibrators - Infect. immunology

Our products

Product category: Auto-immune diseases

Ref. M_GM1

Chimeric human/mouse monoclonal IgM targeting gangliosides GM1.

Gangliosides are glycolipids which mainly take part in the recognition of molecules among cellular membranes. 

The accumulation of gangliosides is often observed among patients with a lysosomic disease. Therefore, antibodies targeting gangliosides are a relevant marker to diagnose this kind of disease. 

More Less

About us

Company details

ArkAb is the sales division of B Cell Design focused on the in vitro diagnostic market. ArkAb offers to IVD companies a reliable, reproducible and secured source of chimeric human antibodies for several purposes:

  • Calibrators, positive controls and quality controls for in vitro diagnostic kits to replace human disease state plasma
  • Immunocapture antibodies to replace mice antibodies which trigger false positive or false negative answers due to HAMA antibodies.
  • Research reagents (development or renewal of diagnostic kits, improvement of the products portfolio…)
B Cell Design develops a new mucosal immunotherapy approach for generating a large number of drug and vaccine candidates in infectious field and oncology. 
This leads to develop two groundbreaking drug candidates:

  • A vaccine candidate in infectious diseases field: a worldwide patented HIV vaccine (A new non-HIV vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against HIV infection – Europe Patent 14305174.6) to prevent or even cure HIV infections. Preliminary studies showed that this approach elicits an efficient local immune response, neutralizing HIV infection of human cells.
  • A drug candidate in oncology field (colorectal cancer) for immunotherapy, radioimmunotherapy applications or medical imaging.
For more information about B Cell Design, please visit www.b-cell-design.com!

More Less